Newly diagnosed heart failure with reduced ejection fraction: timing, sequencing, and titration of guideline-recommended medical therapy
The TITRATE-HF study demonstrates that rapid initiation of GRMT for HFrEF is feasible in real-world clinical practice. Nonetheless, our results highlight the urgency for a proactive approach and ongoing dose titration of pharmacological therapy beyond the initial first months to fully optimize treatment.
Authors
- Eric Wierda (ORCID: https://orcid.org/0000-0002-9998-5035)
- Jasper J. Brugts (ORCID: https://orcid.org/0000-0002-5522-9318)
- Sandra Sanders-van Wijk
- Antonius van Stipdonk (ORCID: https://orcid.org/0000-0002-6621-0727)
- Rudolf A. de Boer (ORCID: https://orcid.org/0000-0002-4775-9140)
- Charlotte E. P. Siegers
- Hans‐Peter Brunner‐La Rocca (ORCID: https://orcid.org/0000-0002-4356-8566)
- Alexander J. Wardeh (ORCID: https://orcid.org/0000-0002-2398-3092)
- Stefan Koudstaal (ORCID: https://orcid.org/0000-0003-4982-6658)
- Mireille E. Emans
- Jishnu Malgie (ORCID: https://orcid.org/0009-0001-1561-3542)
- Jeroen Schaap
- Mieke van den Heuvel
- Grytsje A. de Boer
- Mariëlle I Wilde
Institutions
- Maastricht University Medical Centre (NL)
- Medisch Spectrum Twente (NL)
- Erasmus MC (NL)
- Maastricht University (NL)
- Noordwest Ziekenhuisgroep (NL)
- Medisch Centrum Haaglanden (NL)
- Ikazia Ziekenhuis (NL)
- Amphia Ziekenhuis (NL)
- Zuyderland Medisch Centrum (NL)
- Groene Hart Ziekenhuis (NL)
- Meander Medisch Centrum (NL)
Publication Details
- Journal
- European Heart Journal
- Published
- 2025-03-29
- DOI
- https://doi.org/10.1093/eurheartj/ehaf244
- Citations
- 17
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 23.60
Funders
- Abbott Laboratories
- AstraZeneca
- Dutch Cardiovascular Alliance
- Boehringer Ingelheim España
- ZonMw
- Vifor Pharma
- AstraZeneca Pharma Poland
- Bayer Portugal
- ICIN Netherlands Heart Institute
- Netherlands Heart Institute